Aug 4
|
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
|
Jul 31
|
Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON
|
Jul 29
|
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
|
Jun 13
|
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
|
May 27
|
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
|
May 23
|
Outcome of Innate Pharma’s 2025 Annual General Meeting
|
May 23
|
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
|
Feb 17
|
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
|